Intervention

SRS

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 3 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting1

Common conditions4

Lead sponsors shown3

Clinical trials

3 shown

The CyberChallenge Trial How Much is Too Much - What is the Role of Cyberknife Radiosurgery in Patients With Multiple Brain Metastases?NCT05378633 · 2022-02-24

RECRUITING

Whole Brain Radiation Therapy Alone vs. Radiosurgery for SCLC Patients With 1-10 Brain MetastasesNCT03297788 · 2017-12-01

COMPLETED

High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain MetastasesNCT02726568 · 2016-03-01

UNKNOWN

Common conditions

Brain Metastases3 Non-small Cell Lung Cancer1 Nsclc1 SCLC1

Leading sponsors

Betta Pharmaceuticals Co., Ltd. 1 Juergen Debus 1 University Hospital Heidelberg 1

Trial status mix

COMPLETED1

RECRUITING1

UNKNOWN1

Phase mix

NA2

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.